A citation-based method for searching scientific literature

April W Armstrong, Ahmed M Soliman, Keith A Betts, Yan Wang, Yawen Gao, Vassilis Stakias, Luis Puig. Dermatol Ther (Heidelb) 2022
Times Cited: 6







List of co-cited articles
6 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren. PLoS One 2019
81
33

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
April Armstrong, Kyle Fahrbach, Craig Leonardi, Matthias Augustin, Binod Neupane, Paulina Kazmierska, Marissa Betts, Andreas Freitag, Sandeep Kiri, Vanessa Taieb,[...]. Dermatol Ther (Heidelb) 2022
2
100

Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, Yukari Okubo, Michael M Witte, Claudia Rodriguez Capriles, Angelina Sontag, Vipin Arora, Olawale Osuntokun, Bruce Strober. Br J Dermatol 2022
3
66

Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.
Neil H Shear, Keith A Betts, Ahmed M Soliman, Avani Joshi, Yan Wang, Jing Zhao, Paolo Gisondi, Ranjeeta Sinvhal, April W Armstrong. J Am Acad Dermatol 2021
9
33


Introducing the Treatment Hierarchy Question in Network Meta-Analysis.
Georgia Salanti, Adriani Nikolakopoulou, Orestis Efthimiou, Dimitris Mavridis, Matthias Egger, Ian R White. Am J Epidemiol 2022
4
50

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.
Andrew Blauvelt, Andrea Chiricozzi. Clin Rev Allergy Immunol 2018
250
16


Brodalumab: A new way to inhibit IL-17 in psoriasis.
Paola Facheris, Mario Valenti, Giulia Pavia, Elena Guanziroli, Alessandra Narcisi, Riccardo G Borroni, Antonio Costanzo. Dermatol Ther 2020
7
16

A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis.
Chunlei Zhang, Kexiang Yan, Qingchun Diao, Qing Guo, Hongzhong Jin, Sen Yang, Xiang Chen, Tiechi Lei, Jianhua Wu, Hong Yu,[...]. J Am Acad Dermatol 2022
3
33

No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Therezia Bokor-Billmann, Knut Schäkel. J Dermatolog Treat 2019
17
16

Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
L J van Vugt, J M P A van den Reek, E Meulewaeter, M Hakobjan, N Heddes, T Traks, K Kingo, M Galluzzo, M Talamonti, J Lambert,[...]. J Eur Acad Dermatol Venereol 2020
9
16

Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Delia Colombo, Luca Bianchi, Gabriella Fabbrocini, Salvatore Corrao, Annamaria Offidani, Luca Stingeni, Antonio Costanzo, Giovanni Pellacani, Ketty Peris, Federico Bardazzi,[...]. Dermatol Ther 2022
5
20



Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic, Andrew Blauvelt. J Am Acad Dermatol 2020
25
16

Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry.
Clinton W Enos, Vanessa L Ramos, Robert R McLean, Tin-Chi Lin, Nicole Foster, Blessing Dube, Abby S Van Voorhees. J Am Acad Dermatol 2022
4
25

Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients.
He Huang, Ming-Long Cai, Xiao-Jie Hong, Li-Jun Zheng, Zhu-Lin Hu, Tao Yuan, Wei-Ran Li, Yu-Jun Sheng, Xue-Jun Zhang. Eur J Dermatol 2020
7
16

Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
K Reich, L Puig, J C Szepietowski, C Paul, J P Lacour, A Tsianakas, C Sieder, M Rissler, E Pournara, R Orsenigo. Br J Dermatol 2020
25
16

Treatment of Patients with Cirrhosis.
Pramod Kumar, Sunil Taneja, Virendra Singh. N Engl J Med 2016
6
16


Biological therapy in patients with psoriasis: What we know about the effects on renal function.
Giulia Veronesi, Alba Guglielmo, Aldo Gardini, Lidia Sacchelli, Camilla Loi, Annalisa Patrizi, Federico Bardazzi. Dermatol Ther 2022
2
50

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
Jillian Frieder, Dario Kivelevitch, Alan Menter. Ther Adv Chronic Dis 2018
88
16

Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies.
M Augustin, D Jullien, A Martin, C Peralta. J Eur Acad Dermatol Venereol 2020
32
16

Intermittent use of biologic agents for the treatment of psoriasis in adults.
A Al-Hammadi, Z Ruszczak, G Magariños, C-Y Chu, Y El Dershaby, N Tarcha. J Eur Acad Dermatol Venereol 2021
7
16

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study.
Yan Zhao, Lin Cai, Xiao-Yang Liu, Heng Zhang, Jian-Zhong Zhang. Chin Med J (Engl) 2021
2
50

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper.
G Girolomoni, C E M Griffiths, J Krueger, F O Nestle, J-F Nicolas, J C Prinz, L Puig, M Ståhle, P C M van de Kerkhof, M Allez,[...]. J Dermatolog Treat 2015
30
16


Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab.
Mathias Augustin, Gaia Gallo, Kyoungah See, Missy McKean-Matthews, Russel Burge, Melinda Gooderham, Kristian Reich. J Drugs Dermatol 2022
1
100

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.
Esther von Stebut, Kristian Reich, Diamant Thaçi, Wolfgang Koenig, Andreas Pinter, Andreas Körber, Tienush Rassaf, Ari Waisman, Venkatesh Mani, Denise Yates,[...]. J Invest Dermatol 2019
101
16

Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study.
Si-Man Zhu, Wen-Hui Wang, Jin-Zhu Guo, Xin Guan, Yue-Hua Men, Hua Zhang, Yi-Ming Zhao, Chun-Lei Zhang. Chin Med J (Engl) 2020
2
50

Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review.
C A J Michielsens, M E van Muijen, L M Verhoef, J M P A van den Reek, E M G J de Jong. Drugs 2021
7
16

Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
A Blauvelt, K Reich, R B Warren, J C Szepietowski, B Sigurgeirsson, S K Tyring, I Messina, V Bhosekar, J Oliver, C Papavassilis,[...]. Br J Dermatol 2017
21
16

Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Maria Laura Acosta Felquer, Luciano LoGiudice, Maria Laura Galimberti, Javier Rosa, Luis Mazzuoccolo, Enrique R Soriano. Ann Rheum Dis 2022
15
16


Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.
Tessa L Hanley, Zenas Zn Yiu. Ther Clin Risk Manag 2017
15
16

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
K A Papp, C L Leonardi, A Blauvelt, K Reich, N J Korman, M Ohtsuki, C Paul, S Ball, G S Cameron, J Erickson,[...]. Br J Dermatol 2018
63
16

IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities.
Jackelyn B Golden, Thomas S McCormick, Nicole L Ward. Cytokine 2013
60
16

Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events.
Wayne Gulliver, Michelle Penney, Rebecca Power, Susanne Gulliver, Sonia Montmayeur, Russel Burge. J Dermatolog Treat 2022
2
50

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Richard B Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg. Dermatol Ther (Heidelb) 2020
21
16


Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.
Yu-Chen Chen, Yi-Ting Huang, Chao-Chun Yang, Edward Chia-Cheng Lai, Cheng-Han Liu, Chao-Kai Hsu, Tak-Wah Wong, Sheau-Chiou Chao, Hamm-Ming Sheu, Chaw-Ning Lee. PLoS One 2020
5
20

Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice.
Enrique Herrera-Acosta, Gustavo G Garriga-Martina, Jorge A Suárez-Pérez, Eliseo A Martínez-García, Enrique Herrera-Ceballos. Dermatol Ther 2020
9
16

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
Andrea Chiricozzi, Anna Balato, Curdin Conrad, Andrea Conti, Paolo Dapavo, Paulo Ferreira, Francesca Maria Gaiani, Luiz Leite, Piergiorgio Malagoli, Pedro Mendes-Bastos,[...]. J Dermatolog Treat 2020
16
16

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics.
Alan Menter, April Armstrong, Abby Van Voorhees, Clive Liu, Abby Jacobson. Dermatol Ther (Heidelb) 2020
2
50

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
16

The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
Lisa Lynn Ten Bergen, Aleksandra Petrovic, Anders Krogh Aarebrot, Silke Appel. Scand J Immunol 2020
19
16

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
Ulrich Mrowietz, Craig L Leonardi, Giampiero Girolomoni, Darryl Toth, Akimichi Morita, Shyamal A Balki, Jacek C Szepietowski, Pascaline Regnault, Helen Thurston, Charis Papavassilis. J Am Acad Dermatol 2015
142
16

Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study.
C Kromer, D Wilsmann-Theis, S Gerdes, S Krebs, A Pinter, S Philipp, R Mössner. J Dermatolog Treat 2021
12
16

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
A Blauvelt, C Leonardi, B Elewski, J J Crowley, L C Guenther, M Gooderham, R G Langley, R Vender, A Pinter, C E M Griffiths,[...]. Br J Dermatol 2021
26
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.